CD300C

Across TCGA pan-cancer cohorts, CD300C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD300C data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CD300C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD300C expression acts as an unfavorable survival marker.

HNSC, UCS, and ESCA are the cancer types where CD300C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.130	0.696	.001	36	view →
UCS	OS	Median	II,III,IV	0.001	0.616	<.001	24	view →
ESCA	DFS	Median	II,III,IV	0.172	0.525	.015	9	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD300C–HNSC (DFS)

Open the HNSC breakdown →